Clorox Company Faces Significant Stock Decline Amid Weak Financials

Oakland, California-based The Clorox Company (CLX) produces and markets a wide range of consumer and professional products. The company operates through multiple segments, including Health and Wellness, Household, Lifestyle, and International. With a market capitalization of $17.5 billion, Clorox offers a diverse portfolio of brands available in over 100 countries worldwide.

Eligible firms with market valuations of $10 billion or more are typically classified as “large-cap stocks,” making Clorox a perfect example within this category. Its robust operations and well-known brand portfolio contribute to its impressive valuation.

Recent Market Performance

However, the situation for CLX stocks has deteriorated recently. Shares have decreased by 16.6% from their 52-week high of $171.37 recorded on December 6, 2024. In the last three months, CLX has fallen by 12.8%, underperforming the Dow Jones Industrial Average ($DOWI), which only dipped by 2% in the same period.

Long-term performance further highlights Clorox’s struggles. Over the past six months, CLX stocks have dropped 11.7%, while declining 4.6% over the past year. This starkly contrasts with the Dow, which experienced an uptick of 66 basis points over the same six-month period and 8.1% growth over the past year.

Adding to the negative outlook, Clorox has persistently traded below its 50-day moving average since mid-December and has been below its 200-day moving average since earlier this month.

Q4 Results Raise Concerns

On February 3, Clorox shares saw a significant decline, dropping 7.2% following the release of disappointing Q4 earnings. The company reported a double-digit sales decrease across all segments, with organic revenues declining by 9%. Consequently, total revenue fell 15.3% year-over-year to $1.7 billion. Although Clorox noted a slight improvement in gross margin due to lower costs of goods sold (COGS), the company struggled to turn those gains into profit. Increased advertising and operating expenses led to a 409 basis point contraction in adjusted EBIT margin compared to the same quarter last year, reducing it to 15.3%. This adjustment resulted in a 33.2% year-over-year drop in adjusted EBIT to $258 million.

Moreover, Clorox has also struggled in comparison to competitors, notably Kimberly-Clark Corporation (KMB), which saw only a 1.8% decline over the past six months and a 10.7% increase over the last year.

Analyst Consensus and Outlook

Among the 20 analysts monitoring CLX stocks, the consensus rating remains a “Hold.” The average price target is set at $161.50, indicating a potential upside of 13% based on current pricing.

On the date of publication, Aditya Sarawgi did not hold (either directly or indirectly) positions in any securities mentioned in this article. All information and data are for informational purposes only. For more details, please refer to the Barchart Disclosure Policy here.

More news from Barchart

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.